10:44:37 EST Sun 25 Feb 2024
Enter Symbol
or Name

Login ID:
Titan Medical Inc (2)
Symbol TMD
Shares Issued 111,890,707
Close 2022-11-09 C$ 0.61
Market Cap C$ 68,253,331
Recent Sedar Documents

Titan Medical's Sept. 30 cash at $11.6-million

2022-11-10 16:05 ET - News Release

Mr. Cary Vance reports


Titan Medical Inc. has released financial results for the three and nine months ended Sept. 30, 2022. Additionally, the company announced that a special meeting of shareholders will be held virtually on January 12, 2023 to seek shareholder approval for a consolidation of its common shares, including for the purposes of demonstrating compliance with Nasdaq Rule 5550(a)(2).

As previously shared, Nasdaq granted the company with an extension to regain compliance with Nasdaq Rule 5550(a)(2), which requires an issuer to maintain a minimum bid price of at least US$1.00 for a minimum of 10 consecutive business days (and generally not more than 20 consecutive business days, in Nasdaq's discretion). While the company continues to undertake initiatives directed at increasing shareholder value, should the company not be able to evidence compliance prior to December 26, 2022, the company expects Nasdaq to notify Titan that its shares are subject to delisting. At such time, the company would likely appeal such determination and it is expected that the company's shares would continue to be listed and available to trade on Nasdaq at least pending the completion of the appeal process. The share consolidation, if approved, would likely be the last option available to the company to regain compliance with the minimum bid price requirement and maintain its Nasdaq listing.

"Titan is completing the final steps prior to the anticipated delivery of the first Enos system to its Chapel Hill facility before year-end 2022. We are excited and ready to commence verification, validation and safety testing on the delivered unit in support of the planned IDE submission to the FDA in 2023. Following submission, we expect to finalize our clinical trial design and continue to plan our commercialization strategy for the U.S. market. We have worked closely with our manufacturing partners in an effort to circumvent supply chain disruptions and are excited about our progress to date at this stage of the production cycle. We are committed to working with surgeons to improved patient outcomes using minimally invasive robotic surgery," stated Cary G. Vance, Titan's President and CEO.

Vance added, "After careful consideration, the company has also decided to propose a consolidation of common shares to its shareholders. We believe that a consolidation is in the best interests of shareholders, including for the purposes of regaining compliance with Nasdaq listing requirements. A continued Nasdaq listing provides numerous benefits to the company, including increased visibility of the company amongst U.S. analysts and investors, increased access to capital including potentially institutional investors, and the potential for greater trading volume and liquidity for the company's common shares. We look forward to providing additional details of the special meeting."

Recent Company Activities and Progress

Cary Vance participated on a panel during The MedTech Conference held in Boston on October 24-26, 2022

Mr. Vance and other leaders discussed navigating regulatory and business considerations in surgical robotics innovation

Appointed Eric Heinz as Vice President, Market and Corporate Development

Mr. Heinz is responsible for developing and executing on strategic business plans to expand and accelerate Titan's Enos(TM) robotic single access surgical system's portfolio cadence

Completion of manufacturing transfer to Benchmark

Titan has substantially completed the transfer of the Enos System to manufacturing, including the areas of supply chain management, product assembly and testing, and implementation of software updates related to safety controls

Continued FDA communications via Q-Submission process

Received helpful feedback from the FDA on last Q-submission utilizing this effective process

Continued strengthening of intellectual property

Filings include innovations in next generation single access RAS technology

Signed a limited development and supply agreement with Medtronic

The company will support Medtronic with limited development and pre-clinical activities through the supply of instruments and cameras

Presented at the H.C. Wainwright Global Investment Conference held on September 12-14, 2022 and participated in investor meetings

The company plans to pursue a De Novo regulatory process for marketing authorization with the U.S. Food and Drug Administration (FDA). Utilizing the Q-Submission program, the company has engaged in ongoing dialogue with the FDA to clarify requirements in an effort to mitigate against timeline risks. The company plans to file the IDE application with the FDA mid-year 2023 for its initial target indication for benign gynecologic surgical procedures. Titan anticipates receiving a response on the IDE application from the FDA in the second half of 2023. Following IDE approval, Titan expects to proceed with and complete a clinical study in time for submission of a De Novo classification request with the FDA in 2024. Commercial launch of the Enos(TM) single access RAS system is scheduled to begin upon receipt of marketing authorization from the FDA.

Financial Highlights Summary

As of September 30, 2022, Titan had cash and cash equivalents of $11.6 million, compared to $32.3 million at December 31, 2021.

For the three months ended September 30, 2022, R&D expenses were to $7.6 million compared to $10.7 million for the for the three months ended September 30, 2021. R&D expenses for the three-month period ending September 30, 2022 were related to the development of the Enos System and an increase in labor costs as the Company continues to add the required resources to its engineering, regulatory and quality teams to advance the Enos System.

R&D expenses were $26.7 million for the nine months ended September 30, 2022 compared to $28.4 million for the nine months ended September 30, 2021. R&D expenses for the nine-month period ending September 30, 2022 were related to the development of the Enos System and an increase in labor costs. In the comparative period, R&D expenses related to the development of the Enos System and the development work required to achieve the milestones under the Development Agreement with Medtronic.

G&A expenses were $3.0 million for the three months ended September 30, 2022 compared to $3.4 million for the three months ended September 30, 2021. The decrease in G&A expenses in the three-month period is related to a decrease in stock-based compensation of $0.4 million.

For the nine-month period ended September 30, 2022, G&A expenses were $8.7 million compared to $9.6 million in the comparative period. The decrease in G&A expenses in the nine-month period is primarily related to a decrease in stock-based compensation of $1.8 million and a decrease in professional and consulting fees partially offset by an increase in severance costs, public company costs and recruitment fees related to filling open roles on the senior leadership team.

The company's interim financial statements and MD&A are available at www.sedar.com and at www.sec.gov.

Investor Audio Webcast Information

Titan Medical will host an investor audio webcast at 8:30 a.m. ET today (November 10, 2022) to discuss the company's financial results for the three months ended September 30, 2022, and recent business highlights. The webcast can be accessed via the Investor Relations section of the company's website www.titanmedicalinc.com.

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company headquartered in Toronto, Ontario and with operations in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos(TM) robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.

We seek Safe Harbor.

 Titan Medical Inc.                                                                                     
Interim Consolidated Statements of Net and Comprehensive Loss                                          
(In thousands of US dollars, except share and per share amount)                                        
                                           Three Months Ended Sept 30      Nine Months Ended Sept 30   
                                             2022            2021            2022           2021      
                                                    $               $               $              $  
Revenues                                            -               -               -         10,093  
Research and development                        7,612          10,714          26,721         28,358  
General and administrative                      3,008           3,358           8,668          9,565  
Depreciation                                        -               -               -              -  
Total expenses                                 10,620          14,072          35,389         37,923  
Net loss from operations                      (10,620 )       (14,072 )       (35,389 )      (27,830 )
Other Expenses (Income)                                                                                
Finance income                                    (34 )           (20 )           (95 )          (53 )
Finance expense                                    42              60              77             60  
Foreign exchange (gain) loss                      (34 )            (3 )            (6 )           56  
Gain on fair value of warrant                    (224 )        (5,554 )        (4,891 )       (3,604 )
Total other income                               (250 )        (5,517 )        (4,915 )       (3,541 )
Net and comprehensive loss                    (10,370 )        (8,555 )       (30,474 )      (24,289 )
Basic and fully diluted loss per share          (0.09 )         (0.08 )         (0.27 )        (0.23 )
Weighted average number of common shares                                                               
Basic and diluted                         111,664,823     111,127,690     111,397,231    107,520,004  

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.